GlassScriptPhysician profile
Angela Nishio
NPI 1053320242
$3,047.83
in general payments reported to CMS, 2019-2025
32 companies · $683 in 2025
The $683 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $133 · 2021: $569 · 2022: $336 · 2023: $759 · 2024: $347 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $495.19 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $467.56 | 2021-2025 | |
| Pfizer INC. | $203.98 | 2023-2025 | |
| Hologic Sales and Service, LLC | $188.87 | 2022-2025 | Aptima, Acessa Provu System, Thinprep 2000 Processor |
| Agile Therapeutics, INC. | $170.12 | 2021-2024 | Twirla |
| Therapeuticsmd, INC. | $164.05 | 2019-2022 | |
| Astellas Pharma US INC | $155.10 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $146.26 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $135.38 | 2025 | Zurzuvae |
| Novo Nordisk INC | $122.41 | 2023 | |
| Becton, Dickinson and Company | $73.67 | 2023-2024 | Bd Onclarity |
| Evofem Biosciences, INC. | $70.89 | 2021-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $69.85 | 2019-2021 | |
| Myovant Sciences INC. | $68.33 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.50 | 2020-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.28 | 2020 | |
| Myriad Women'S Health, INC. | $41.88 | 2023 | |
| Scynexis, INC. | $39.87 | 2022 | |
| Millicent US INC | $39.02 | 2025 | Femlyv, Intrarosa |
| Merck Sharp & Dohme LLC | $36.17 | 2019 | |
| Aspira Women'S Health INC | $31.67 | 2021 | |
| Boston Scientific Corporation | $31.00 | 2024 | Advantage System |
| Smith+Nephew, INC. | $24.99 | 2023 | Pico |
| Minerva Surgical, INC | $23.83 | 2023 | |
| Amag Pharmaceuticals, INC. | $22.14 | 2019 | |
| Exact Sciences Corporation | $20.05 | 2025 | Cologuard Collection Kit |
| Organon LLC | $17.56 | 2022 | |
| Baxter Healthcare | $17.37 | 2023 | Perclot |
| Channel Medsystems, INC. | $16.33 | 2023 | |
| Alydia Health | $16.11 | 2021 | |
| Ascend Therapeutics US, LLC | $14.24 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.16 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Nishio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.